Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rocklatan (Roclanda - EU) (netarsudil (ROCK - rho kinase inhib) & latanoprost (ophthalmic solution) Details Ophthalmology, IOP (intra-ocular pressure) | Approved Quarterly sales | |
Approved Quarterly sales | ||
AR-15512 (TRPM8 agonist eye drop) Details Eye disease , Dry eye syndrome, Opthalmolgy, Metastatic merkel cell carcinoma | Phase 3 Data readout | |
AR-1105 Details Eye disease , Diabetic macular edema, Diabetes | Phase 3 Update |